HRD	Prostate Cancer	HRD	Prostate Cancer	talazoparib + enzalutamide capsule Sensitive: A1 - Approval Nat Med - 5 days (New B) talazoparib + enzalutamide capsule Sensitive : A1 Nat Med - 5d	talazoparib + enzalutamide capsule Sensitive: A1 - Approval Nat Med - 5 days talazoparib + enzalutamide capsule Sensitive : A1 Nat Med - 5 days - (New B)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline ESMO Asia 2023 - 1 week (New B) niraparib Sensitive : A2 ESMO Asia 2023 - 1wk	niraparib Sensitive: A2 - Guideline ESMO Asia 2023 - 1 week niraparib Sensitive : A2 ESMO Asia 2023 - 1 week - (New B)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	niraparib Sensitive: A2 - Guideline ESMO Asia 2023 - 1 week (New B) niraparib Sensitive : A2 ESMO Asia 2023 - 1wk	niraparib Sensitive: A2 - Guideline ESMO Asia 2023 - 1 week niraparib Sensitive : A2 ESMO Asia 2023 - 1 week - (New B)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	Androgen receptor inhibitor Resistant: C3 – Early Trials ESMO Asia 2023 - 1 week (New C3) Androgen receptor inhibitor Resistant : C3 ESMO Asia 2023 - 1wk	Androgen receptor inhibitor Resistant: C3 – Early Trials ESMO Asia 2023 - 1 week Androgen receptor inhibitor Resistant : C3 ESMO Asia 2023 - 1 week - (New C3)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	Androgen receptor inhibitor Resistant: C3 – Early Trials ESMO Asia 2023 - 1 week (New C3) Androgen receptor inhibitor Resistant : C3 ESMO Asia 2023 - 1wk	Androgen receptor inhibitor Resistant: C3 – Early Trials ESMO Asia 2023 - 1 week Androgen receptor inhibitor Resistant : C3 ESMO Asia 2023 - 1 week - (New C3)
HRD	Prostate Cancer	HRD	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week (New C3) PARP inhibitor Sensitive : C3 ESMO Asia 2023 - 1wk	PARP inhibitor Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week PARP inhibitor Sensitive : C3 ESMO Asia 2023 - 1 week - (New C3)
CYP11B1 rs4736349	Prostate Cancer	CYP11B1 rs4736349	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials Biomed Pharmacother - 2 weeks (New C3) abiraterone acetate Resistant : C3 Biomed Pharmacother - 2wk	abiraterone acetate Resistant: C3 – Early Trials Biomed Pharmacother - 2 weeks abiraterone acetate Resistant : C3 Biomed Pharmacother - 2 weeks - (New C3)
CYP11B1 rs4736349	Prostate Cancer	CYP11B1 rs4736349	Prostate Cancer	enzalutamide capsule Resistant: C3 – Early Trials Biomed Pharmacother - 2 weeks (New C3) enzalutamide capsule Resistant : C3 Biomed Pharmacother - 2wk	enzalutamide capsule Resistant: C3 – Early Trials Biomed Pharmacother - 2 weeks enzalutamide capsule Resistant : C3 Biomed Pharmacother - 2 weeks - (New C3)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	talazoparib + enzalutamide capsule Sensitive: B - Late Trials Pfizer Press Release - 3 weeks (New B) talazoparib + enzalutamide capsule Sensitive : B Pfizer Press Release - 3wk	talazoparib + enzalutamide capsule Sensitive: B - Late Trials Pfizer Press Release - 3 weeks talazoparib + enzalutamide capsule Sensitive : B Pfizer Press Release - 3 weeks - (New B)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval J Clin Oncol - 3 weeks (New B) olaparib Sensitive : A1 J Clin Oncol - 3wk	olaparib Sensitive: A1 - Approval J Clin Oncol - 3 weeks olaparib Sensitive : A1 J Clin Oncol - 3 weeks - (New B)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval J Clin Oncol - 3 weeks (New B) olaparib Sensitive : A1 J Clin Oncol - 3wk	olaparib Sensitive: A1 - Approval J Clin Oncol - 3 weeks olaparib Sensitive : A1 J Clin Oncol - 3 weeks - (New B)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1	enzalutamide capsule Sensitive: A1 - Approval enzalutamide capsule Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel Sensitive: A1 - Approval docetaxel Sensitive : A1	docetaxel Sensitive: A1 - Approval docetaxel Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel Sensitive: A1 - Approval docetaxel Sensitive : A1	docetaxel Sensitive: A1 - Approval docetaxel Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
HRD	Prostate Cancer	HRD	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1	zoledronic acid Sensitive: A1 - Approval zoledronic acid Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate + flutamide Sensitive: A1 - Approval goserelin acetate + flutamide Sensitive : A1	goserelin acetate + flutamide Sensitive: A1 - Approval goserelin acetate + flutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate Sensitive: A1 - Approval goserelin acetate Sensitive : A1	goserelin acetate Sensitive: A1 - Approval goserelin acetate Sensitive : A1
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide 6-month depot Sensitive: A1 - Approval leuprolide 6-month depot Sensitive : A1	leuprolide 6-month depot Sensitive: A1 - Approval leuprolide 6-month depot Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprorelin depot Sensitive: A1 - Approval leuprorelin depot Sensitive : A1	leuprorelin depot Sensitive: A1 - Approval leuprorelin depot Sensitive : A1
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
CDK12 mutation	Prostate Cancer	CDK12 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK2 mutation	Prostate Cancer	CHEK2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
CHEK1 mutation	Prostate Cancer	CHEK1 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2	abiraterone acetate Resistant: A2 - Guideline abiraterone acetate Resistant : A2

Prostate Cancer

Associations(491)

Associations
(491)